Royalty Report: Drugs, Biotechnology, cardiac – Collection: 7393


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • cardiac
  • Stem cells

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7393

License Grant
The Licensor has entered into a License Agreement with the Licensee, of Moscow Russia, giving that firm License rights to ERCs (Endometrial Regenerative Cells) for CHF (Congestive Heart Failure) indications in the territory of Russia.
Licensor acknowledges that he has the exclusive right to use the know-how, the exclusive right to permit other persons to use it, and the exclusive right to prevent any unauthorised disclosure and (or) other use of this know-how, and is entitled to dispose of its at his discretion in compliance with the above specified rights.
License Property
In January 2012, the Licensor announced the initiation of the RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde Coronary Sinus Venous Delivery of Cell Therapy) Phase II clinical trial.

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function.

Field of Use
The Licensee is providing sponsorship and funding for ongoing Phase II clinical trial in CHF being conducted at the Bakulev Scientific Center for Cardiovascular Surgery.

IPSCIO Record ID: 28172

License Grant
The Licensor, a nonprofit American academic medical center, grants to the Belgium Licensee an exclusive license to make, have made, use, modify, enhance, promote, market and/or sell the Licensed Invention whether or not patented, and a non-exclusive right to use the Licensed Know-How, in the Territory within the Field of Heart Disease.
The Licensee may assigning or subcontract the rights with permission from the Licensor.
License Property
Licensed inventions means Cardiogenic Cocktail for the production of Cardiac Cells and Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure.

2004-182 Derivation of a Cardiopoetic Cellular Phenotype from a Stem Cell Source.

And the related Patents and Patent Applications;

06/592,871 Stem Cells and treatment of Vascular Tissue

06/680,775 Treating Cardiovascular Tissue

06/832,845 Methods and Materials for providing Cardiac Cells

PCT/US2005/026800 Treating Cardiovascular Tissue

PCT/US2008/064895 Methods and Materials for using Cells to treat Heart Tissue

PCT/US2009/044714 Compositions and Methods for Using Cells to treat Heart Tissue

PCT/US2009/044751 Methods for determining the Cardio Generative Potential of Mammalian Cells

3. Paragraph 2.02 is replaced with the following;

Field of Use
FIELD OF USE means cardiovascular regeneration or protection.

Field of Use means treatment of embryonic and autologus mesenchymal stem cells to guide development into cardiomyocytes for the treatment of myocardial infarction, ischemic heart disease, ischemic and non-ischemic cardiomyopathy.

The Belgian biopharma company is involved in the discovery, development and commercialisation of regenerative and protective therapies for the treatment of cardiac diseases.

IPSCIO Record ID: 3304

License Grant
The Undisclosed Licensee entered into an exclusive License Agreement with this unrelated Chinese-based Licensor to develop and commercialize hepatocellular carcinoma stem cells in the territory of China, Hong Kong, Macau, and Taiwan. The Agreement has an initial term of seven years.
License Property
Hepatocellular carcinoma stem cells – Cells of the Iiver.
Field of Use
The Licensee develops cell based therapeutics that prevent, treat, cure, or regenerate damaged or aged tissue, cells and organs and restoring their normal function.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.